Bladder Cancer FAQ
Bladder Cancer FAQ
The questions below are the practical ones — what treatment costs, how long you stay, which medicines are available, how records travel and what happens once you are home. Conceptual questions are answered on the overview page .
What treatment costs
The figures most patients are looking for are comparative rather than absolute, and the reliable statement we can make is this: treatment in China typically costs 30% to 50% of the equivalent treatment in Europe or the United States. A formal quotation is prepared from your own records rather than from a published price list.
- The procedure — a transurethral resection, a course of intravesical therapy, a radical cystectomy with diversion, or chemoradiotherapy.
- Hospital days — a resection is a short admission, whereas cystectomy involves a stay measured in days and is the largest single component.
- Medicines — intravesical agents, chemotherapy and targeted drugs differ substantially in price.
- Imaging and re-assessment — repeat imaging, second resections and pathology review.
- Reconstruction and support — the type of urinary diversion, Ostomy supplies and any rehabilitation.
What the total consists of is worth breaking down separately:
The comparison above is a range across our network rather than a quoted price for your case. And the total is not only the hospital bill: travel, accommodation and the length of stay are real costs, which is why the section below is worth reading together with this one.
How long you stay
How long treatment keeps you in China depends almost entirely on which route you are on, and the difference between them is large enough to plan for from the beginning:
- Transurethral resection — usually one to two days in hospital. A second resection, where indicated, is scheduled a few weeks later.
- Intravesical therapy — day-case visits rather than a continuous stay, spreading over weeks for induction and over months or years for maintenance.
- Neoadjuvant chemotherapy — cycles over roughly three months before surgery, each requiring a short admission or day-unit visit.
- Radical cystectomy — a hospital stay measured in days, then several weeks of recovery before flying. This route most determines how long you stay.
- Chemoradiotherapy — daily treatment over several weeks as an outpatient.
Flying after major surgery is subject to a fitness assessment, and the interval varies between patients, so return travel should not be booked tightly against a discharge date. Because surveillance cystoscopy continues for years, most patients arrange follow-up partly at home and partly with us — a schedule best agreed before the first trip.
Which medicines are available
The medicines used for bladder cancer in our network are the ones in current international use. The question patients most often ask is whether the particular medicine they need is available here:
- Intravesical chemotherapy — mitomycin C for a single immediate instillation after resection.
- BCG immunotherapy — for intermediate and high-risk non-muscle-invasive disease, as induction with maintenance.
- Platinum-based chemotherapy — gemcitabine with cisplatin, or a dose-dense combination, for muscle-invasive and advanced disease, including before and after surgery and concurrently with radiotherapy in a bladder-preserving plan.
- Immune checkpoint inhibitors — pembrolizumab and related agents, for BCG-unresponsive and advanced disease.
- Antibody-drug conjugates — enfortumab vedotin, directed at Nectin-4, with immunotherapy for advanced disease.
- FGFR inhibitors — erdafitinib, for tumours with an activating FGFR3 alteration, with molecular testing arranged beforehand.
- Bone-modifying agents — where disease has reached the skeleton.
One medicine needs to be confirmed in advance rather than assumed: BCG, which has at times been in short supply globally, so whether the maintenance doses can be given on schedule should be confirmed in writing before you travel rather than discovered on arrival. Otherwise, whether a specific agent is right for you depends on markers such as Nectin-4, PD-L1 and FGFR3, on what treatment has already been given, and on whether kidney function allows it — questions that a record assessment answers together. Availability of a particular agent also depends on the hospital and on the stage being treated, and should be confirmed in writing.
Sending records and getting a written answer
An assessment can be made before you travel, and the quality of the answer depends on what is sent. For bladder cancer, five items make the difference:
- The resection pathology report — grade, depth of invasion, whether muscle was present, and whether carcinoma in situ was reported.
- The cystoscopy findings, and the cytology result if one was done.
- CT urography, and any MRI of the bladder, as images rather than only as reports where possible.
- The treatment record so far — which intravesical regimen, how many doses, and whether chemotherapy or radiotherapy has been given.
- Recent blood tests and kidney function, which determine whether cisplatin can be used.
Records in English are assessed directly; records in another language are translated by our team. Where an item is missing — most often the muscle statement in the pathology report, or the upper-tract imaging — we will say so explicitly, because those are the gaps that prevent a route from being stated with confidence. The written assessment follows within 48 hours of the file being complete.
Insurance and payment
Bladder cancer treatment involves a procedure and then a surveillance schedule, and both need to be considered when you plan how to pay:
- Direct billing — our network has arrangements with more than 55 insurers, allowing eligible patients to be treated without settling the full amount in advance.
- Confirmation before travel — a pre-authorisation is best obtained before arrival, because a procedure arranged at short notice is difficult to authorise retrospectively.
- Coverage of intravesical therapy — commonly covered as inpatient or day-case treatment; the maintenance schedule should be approved as a course rather than dose by dose.
- Coverage of surgery and diversion — cystectomy and reconstruction are usually covered, and stoma supplies may be handled separately.
- Self-payment — a formal quotation and an itemised estimate are provided on request.
Two points are worth checking with your insurer early: whether the policy covers treatment outside your country of residence, and whether it covers the systemic agents used in advanced disease, where policies vary more than for surgery.
After treatment, and back home
The period after treatment is where bladder cancer differs from many other cancers, because surveillance is long. What should be arranged before you leave:
- A written surveillance schedule — the interval for cystoscopy, how many years it continues, and whether upper-tract imaging is included.
- A record of the intravesical regimen — which agent, how many doses have been given and how many remain.
- Pathology and imaging on disc — so a clinician at home can compare future findings against the baseline.
- Instructions on what to watch for — visible blood in the urine, irritative symptoms that persist, fever after BCG, and difficulty passing urine.
- A named contact — for questions between visits, including arrangements for a video review.
Continuity of intravesical treatment matters more than the address at which it is given: if maintenance doses are completed at home, the drug, the dose and the interval should be documented rather than described. Because recurrence is common and is not a failure of the first treatment, the schedule should read as a plan rather than a precaution.
Eating and daily life during treatment
There is no diet that treats bladder cancer, and any suggestion otherwise should be treated with caution. What nutrition advice can legitimately do is support you through treatment:
- Hydration — drinking adequately is reasonable for general urinary comfort, particularly after intravesical treatment and bladder surgery.
- After cystectomy — bowel is used in the reconstruction, so the diet is advanced gradually and a dietitian review is part of the plan.
- During chemotherapy — adequate protein and calories to maintain weight, and managing nausea and taste changes, matter more than any specific food.
- Supplements — check with the team first, because some interact with treatment.
Bladder irritants such as caffeine, alcohol and spicy food do not cause the cancer and need not be eliminated, though some patients find reducing them eases urinary symptoms after intravesical therapy. If weight loss or difficulty eating becomes a problem, say so early: nutritional support has a real effect on how well people tolerate treatment.